Open AccessPIK3CA Mutations and Neoadjuvant Therapy Outcome in Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: A Sequential Analysis
Author(s) -
Youjeong Seo,
Yeon Hee Park,
Jin Seok Ahn,
YoungHyuck Im,
Seok Jin Nam,
Soo Youn Cho,
Eun Yoon Cho
Publication year - 2018
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2018.21.e48
Subject(s) - medicine , breast cancer , hazard ratio , human epidermal growth factor receptor 2 , oncology , confidence interval , mutation , chemotherapy , trastuzumab , cancer , neoadjuvant therapy , biology , gene , genetics
PIK3CA mutation is considered to be a possible cause for resistance to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer. We investigated the association between PIK3CA mutations and the outcome of NAC in HER2-positive breast cancers.